中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Sleep Assessment in CML

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态
赞助商
HaEmek Medical Center, Israel
合作者
The Max Stern Academic College Of Emek Yezreel

关键词

抽象

Patients with CML report on fatigue, and many of them report on sleep disturbances. The investigators wish to objectively assess the patient's sleep using a sleep "wrist watch" (Actigraph) , and correlate data with their perception of sleep quality. A matched participants group will serve as control. the Control group is defined as participants not having CML or any other malignancy and without any known sleep disturbances.

描述

The investigators will contact the CML patients cohort (about 50) and ask them to join the study. Those consenting will be briefed on the use of an Actigraph wrist device, which the patients should wear for a week. In addition, patients will fill quality of life, depression and anxiety questionnaires.

During the assessment week they will be asked to fill in a short "sleep diary" to be correlated with the objective Actigraph results.

The investigators will analyze objective data and compare to the subjective report of patient's sleep and compare these results with a matched cohort of the control participants. The investigators will analyze the quality of life, anxiety and depression scores also.

The main objective of the study is to try and find a correlation between CML and sleep disturbances, several previous studies found sleep disturbances in reported questionnaires, but the sleep parameters were never studied objectively. Also most of the studies concentrated on the fatigue as the main symptom, in our study the investigators will focus on sleep quality and quantity as a primary symptom.

The quality of life questionnaire will be WHOQOL-BREF questionnaire. The anxiety questionnaire will be Hamilton Anxiety Rating Scale. The depression questionnaire will be Beck Depression Inventory.

The sleep watch that will be used is called Actigraph/Actiwatch and it is FDA approved device, this device will help the investigators assess and observe the objective sleep parameters like length of sleep, time to fall asleep, number of awakenings at night.

There will be no intervention in the study, the results will not alter the treatment the patients receive. But if some patients will be found to have a severe depression or anxiety they will be referred to psychiatric consult.

the study will be with the collaboration of Professor Iris Haymov, sleep researcher from the Max Stern Academic College of Emek Yezreel.

日期

最后验证: 10/31/2017
首次提交: 11/15/2017
提交的预估入学人数: 11/19/2017
首次发布: 11/26/2017
上次提交的更新: 11/25/2017
最近更新发布: 11/27/2017
实际学习开始日期: 11/30/2017
预计主要完成日期: 04/30/2018
预计完成日期: 11/30/2018

状况或疾病

Sleep Disorder
Chronic Myeloid Leukemia

干预/治疗

Device: Actigraph

-

手臂组

干预/治疗
Study Group (CML group)
This group will be CML patients. In this group each participant will be asked to wear a watch "Actigraph" for one week. He will be asked to fill the appropriate questionnaires, and a daily sleep diary.
Control Group
The control group will be non-CML patients, also without any known malignancy or known sleep disturbances. They will be asked to wear the watch "Actigraph" for one week, and to fill the appropriate questionnaires and a daily sleep diary.

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
取样方式Probability Sample
接受健康志愿者
标准

Inclusion Criteria:

- CML patients

- Without known sleep disturbances that are not related to the disease

Exclusion Criteria:

- Malignancy other than CML

- Known sleep disturbances

- Pregnant women

结果

主要结果指标

1. Prevalence of subjective and objective sleep disturbances among patients with CML [1 week of sleep parameters measuring]

The prevalence will be compared to the Control group in the study and to the prevalnce of sleep disturbances reported in other studies.

次要成果指标

1. Comparison between the subjective sleep disturbances reported and the objective sleep disturbances measured in the CML patients group. [1 week]

The investigators will correlate between the subjective and the objective results. the investigators will seek correlation between the anxiety, quality of life and depression questionnaires and the subjective reports of sleep disturbances and whether these reports supported objectively or not

2. Correlation of objective sleep disturbances with the CML patients characteristics. [1 week]

The characteristics that will be used will be: the duration of the disease, the clinical response to therapy, the type of therapy that the patients receive.

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge